文献速递脊柱关节炎

C反应蛋白对中轴型脊柱关节炎白介素-17抑制剂与肿瘤坏死因子抑制剂疗效的影响:丹麦全国观察性研究

Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study.
PubMed 文献 · RMD Open · 2026-06-16

该丹麦全国观察性研究基于DANBIO注册库,纳入2015–2024年首次启用IL-17i或TNFi的3387例axSpA患者,按基线CRP分层分析12个月治疗留存与BASDAI缓解。结果显示,较高基线CRP与首个TNFi留存率提高相关,但与首个IL-17i留存无明确关联;较高CRP与两类药物缓解率提高均相关。

要点

  • IL-17i主要用于TNFi经治患者,TNFi主要用于生物制剂初治患者。
  • 较高基线CRP与首个TNFi留存率提高相关,但与首个IL-17i留存无明确关联。
  • 较高基线CRP与IL-17i和TNFi的BASDAI缓解率提高均相关。

核心结论

  • 在常规诊疗中,较高基线CRP水平与首个TNFi留存率提高相关,但与首个IL-17i留存无明确关联。
  • 较高基线CRP水平与IL-17i和TNFi的BASDAI缓解率提高均相关。

研究设计与样本

  • 丹麦全国观察性研究,基于DANBIO注册库纳入2015–2024年首次启用IL-17i或TNFi的axSpA患者3387例(IL-17i 601例,TNFi 2786例)。
  • 按基线CRP水平分层(低<5、中5-10、高>10 mg/L),采用Kaplan-Meier法和Cox回归分别评估IL-17i与TNFi的12个月治疗留存及停药风险。

主要发现

  • IL-17i组基线CRP低/中/高比例为57%/17%/26%,TNFi组为48%/20%/32%。
  • IL-17i组95%为TNFi经治患者,TNFi组99%为生物制剂初治患者。
  • 12个月留存率按基线CRP低/中/高分層:IL-17i为51%/53%/55%,TNFi为63%/66%/72%,按性别和影像学状态分层结果相似。
  • 以低CRP为参照,IL-17i组中CRP的HR为0.96(95%CI 0.68–1.19)、高CRP的HR为0.90(95%CI 0.68–1.19);TNFi组中CRP的HR为0.86(95%CI 0.73–1.02)、高CRP的HR为0.72(95%CI 0.62–0.84)。
  • BASDAI缓解率按基线CRP低/中/高分層:IL-17i为6%/8%/11%,TNFi为19%/22%/32%。

关键数值与推荐

  • 基线CRP分层界值:低<5 mg/L、中5-10 mg/L、高>10 mg/L。
  • 主要结局为12个月治疗留存和BASDAI缓解。

临床怎么用

  • 对于拟启用首个TNFi的axSpA患者,较高基线CRP提示治疗留存可能更优。
  • 对于拟启用首个IL-17i的患者(多为TNFi经治),基线CRP对留存无明确预测价值,但较高CRP与更高缓解率相关。

局限性

  • 观察性研究设计,存在混杂可能;IL-17i与TNFi组患者既往生物制剂暴露不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the impact of C reactive protein (CRP) level at treatment start on interleukin-17 inhibitor (IL-17i) and tumour necrosis factor inhibitor (TNFi) effectiveness, including treatment retention, in axial spondyloarthritis (axSpA). METHODS: Nationwide observational study including patients with axSpA from the DANBIO registry initiating their first IL-17i or first TNFi between 2015 and 2024. Outcomes were 12-month treatment retention and Bath Ankylosing Spondylitis Disease Activity Index remission stratified by CRP levels (<5 (low)/5-10 (intermediate)/>10 mg/L (high)) at treatment initiation (baseline). Kaplan-Meier plots (including substratification by sex and radiographic status) and Cox regression models were used to assess treatment retention and hazard of discontinuation for IL-17i and TNFi separately. RESULTS: Overall, 3387 patients were included (601 IL-17i, 2786 TNFi) with baseline CRP levels (low/intermediate/high) 57%/17%/26% for IL-17i and 48%/20%/32% for TNFi. For IL-17i, 95% of patients were TNFi-experienced; for TNFi, 99% were biologic-naïve.The 12-month retention rates stratified by baseline CRP (low/intermediate/high) were 51%/53%/55% for IL-17i and 63%/66%/72% for TNFi, with similar results when stratified by sex and radiographic status. Cox models (reference: low CRP) showed no clear association between CRP level and treatment retention among patients receiving IL-17i (intermediate CRP: HR 0.96, 95% CI 0.68 to 1.19; high CRP: HR 0.90, 95% CI 0.68 to 1.19). In contrast, among patients receiving TNFi, intermediate and high CRP levels were associated with a lower risk of treatment discontinuation (HR 0.86, 95% CI 0.73 to 1.02 and HR 0.72, 95% CI 0.62 to 0.84, respectively). Remission rates were 6%/8%/11% for IL-17i and 19%/22%/32% for TNFi. CONCLUSION: In routine care, IL-17i was mainly used in biologic-experienced patients, whereas TNFi was primarily used in biologic-naïve patients with axSpA. Higher baseline CRP levels were associated with higher retention for first TNFi but not for first IL-17i. Higher CRP was associated with higher remission rates for both IL-17i and TNFi.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Høegh Pedersen A, Jensen KY, Hetland ML, et al. Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study. RMD Open. 2026. PMID: 42303383. doi:10.1136/rmdopen-2026-006807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。